Anzeige
Mehr »
Login
Dienstag, 03.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Eilmeldung: Goldshores aggressiver Winter-Explorationsplan nimmt Gestalt an
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
454 Leser
Artikel bewerten:
(2)

Pierre Dodion, MD, MBA, rejoins Alacrita as Partner

Finanznachrichten News

WALTHAM, MA, Nov. 11, 2020 /PRNewswire/ -- Alacrita, a leading life science consulting firm, is delighted to announce that Pierre Dodion, MD, MBA, has rejoined the firm as Partner. He previously worked as a member of the Alacrita Consulting team from 2013-2014. Pierre is a senior pharmaceutical physician and executive with over 30 years of global experience, in both large pharma and biotech. He will consult with clients on a range of activities including strategy, clinical development, and medical affairs. Pierre possesses a rarely-matched background that combines commercial and operational proficiency with medical and clinical expertise. His extensive experience with oncology therapeutics is consistent with Alacrita's position as a leading consulting firm in the field.

Prior to returning to Alacrita, Pierre served as Executive Vice President and Chief Medical Officer of Innate Pharmaceuticals, a biopharmaceutical company developing therapeutic antibodies. While there he provided strategic oversight and oversaw clinical development, medical affairs, biostatistics, clinical operations, safety, and regulatory affairs. In his earlier career, Pierre held the position of Senior Vice President, Corporate Development and Operations at ARIAD. During his tenure, he played a major role in the ARIAD expansion, playing a lead role in the setup of commercial operations (commercial, business, financial, legal and operational) in Europe and Canada, including the appointment of the company's leadership in those regions. Pierre has also held senior leadership roles at Aventis, Novartis, Pfizer, Sanofi and Roche.

Throughout his career, Pierre has developed and demonstrated his expertise with commercial and strategic initiatives, clinical research and development, and medical affairs, including the setup and execution of numerous clinical trials, successful worldwide NDA approvals and the launches of key oncology products in major markets.

Anthony Walker, Managing Partner at Alacrita commented, "Pierre has always been a fantastic consultant. We could not be more pleased to be working alongside him again, offering clients access to his wealth of knowledge and experience, specifically with the development and commercialization of oncology therapeutics."

Alastair Southwell, Head of US Consulting, added "consultants with truly leading expertise in multiple disciplines are rare. It is critical for us to be able to provide our clients with comprehensive advice that balances strategic and operational dimensions. We're very excited to have Pierre back with us."

Pierre Dodion, Partner said of his return, "I'm excited to be starting this new chapter with Alacrita and to have the chance again to work with a truly professional and skilled team. I look forward to providing my expertise to clients, contributing to both their success and the success of the firm."

About Alacrita

Alacrita conducts more than 250 successful client assignments every year and offers US & EU expertise, spanning the disciplines of strategy and commercialization, product development and business development. In addition to our core team, Alacrita has at its disposition a broad network of specialized consultants who can be engaged as necessary when additional, specialized expertise is required. Learn more by visiting www.alacrita.com.

For further information on Alacrita's life science consulting practice, please contact:

Alastair Southwell, Head of US Consulting
Email: usa@alacrita.com
Telephone: +1-617-714-9696
Address: 303 Wyman Street, Waltham, MA 02451

Simon Turner, Managing Partner, Europe
Email: europe@alacrita.com
Telephone: +44-(0)207-691-4915
Address: London BioScience Innovation Centre, 2 Royal College St, London, United Kingdom

© 2020 PR Newswire
5 heiße Wetten für den Jahresendspurt!
Nach dem unerwartet schnellen Ende der US-Wahlen mit dem Sieg des republikanischen Kandidaten Donald Trump fackelten die Aktien- und Krypto- Märkte ein wahres Kursfeuerwerk ab und bliesen zur Jahresendrallye.

Im aktuellen kostenlosen Report beleuchten wir 5 aussichtsreiche Unternehmen, die das Fundament besitzen, in den nächsten Monaten den breiten Markt zu schlagen.

Seien Sie dabei!

Fordern Sie jetzt unseren brandneuen neuen Spezialreport an und erfahren Sie, welche Aktien aufgrund ihrer Bewertung sowie charttechnischen Situation das Potenzial zu einer Outperformance besitzen.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.